Projects

International

Repetitive Subconcussive Head Impacts -Brain Alterations and Clinical Consequences
Repetitive Subconcussive Head Impacts -Brain Alterations and Clinical Consequences
Program: ERANET
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.1.2017 – 31.12.2019
AxonRepair – –
Spinal cord repair: releasing the neuron-intrinsic brake on axon regeneration
Program: ERANET
Project leader: doc. MVDr. Čížková Daša DrSc.
Duration: 1.1.2017 – 31.12.2019
JPsustaiND – Coordination Action in support of the sustainability and globalisation of the Joint Programming Initiative on Neurodegenerative Diseases
Coordination Action in support of the sustainability and globalisation of the Joint Programming Initiative on Neurodegenerative Diseases
Program: Horizon 2020
Project leader: Dr. h. c. prof. MVDr. Novák Michal DrSc.
Duration: 1.11.2015 – 1.11.2019
REfrAME – Mechanizmy patologickej transformácie proteínov pri neurodegeneračných ochoreniach: nové prístupy vyhodnotenia rizík a vývoj modelov
Pathway complexities of protein misfolding in neurodegenerative diseases: a novel approach to risks evaluation and model development
Program: Horizon 2020
Project leader: Dr. h. c. prof. MVDr. Novák Michal DrSc.
Duration: 1.5.2016 – 30.4.2019
NGP-NET – Ne-globulárne bielkoviny, ich sekvencia, štruktúra, funkcia a zapojenie v molekulárnej normálnej a patologickej fyziológii
Non-globular proteins – from sequence to structure, function and application in molecular physiopathology (NGP-NET)
Program: COST
Project leader: RNDr. Škrabana Rostislav PhD.
Annotation: Non-globular proteins (NGPs) encompass different molecular phenomena that defy the traditional sequence-structure-function paradigm. NGPs include intrinsically disordered regions, tandem repeats, aggregating domains, low-complexity sequences and transmembrane domains. Although growing evidence suggests that NGPs are central to many human diseases, functional annotation is very limited. It was recently estimated that close to 40 of all residues in the human proteome lack functional annotation and many of these are NGPs. While a better understanding of NGPs is crucial to fully comprehend human molecular physiopathology, progress has been hampered so far by the lack of a systematic approach to their study.This Action Proposal aims to create a pan-European scientific network of groups that work on NGPs to strengthen, focus and coordinate research in this field. It proposes to develop a novel classification of NGPs by consensus among interested experts that will be showcased on a newly developed web site, along with meetings, training schools and scientific missions on NGP-related topics.
Duration: 31.5.2015 – 25.3.2019
BIOMARKAPD – Biomarkery pre Alzheimerovu a Parkinsonovu chorobu
Biomarkers for Alzheimer’s disease and Parkinson’s disease
Program: Multilateral – other
Project leader: Doc. MVDr. Žilka Norbert DrSc.
Annotation: Neurodegenerative disorders, represented mostly by Alzheimer’s disease (AD) and Parkinson’sdisease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain’sknown capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimedat inhibiting neurodegenerative processes are likely to be most effective if the treatment is initiated asearly as possible in the disease process. However, clinical manifestations in early disease stages areoften difficult to diagnose. This is where biomarkers, specifically reflecting the onset of pathology mayhave a profound impact on diagnosis and detection of treatment effects in the near future. A triplet ofcerebrospinal fluid (CSF) biomarkers for AD, total and hyperphosphorylated tau that reflect AD-typeaxonal degeneration, and the 42 amino acid isoform of amyloid beta that reflects senile plaque pathology, has already been established for early detection of AD before the onset of dementia. With regards to PD, the most promising biomarker is CSF alpha-synuclein. However, large variations in all biomarker measurements have been reported between studies, both between and within centres andlaboratories. Such variations may be caused by pre-analytical, analytical, or assay-related factors andseriously jeopardize the introduction of biomarkers in clinical routine and trials around the world.
Duration: 1.6.2012 – 1.6.2015
NANONET – Nanomechanika sietí intermediálnych filamentov
NANOMECHANICS OF INTERMEDIATE FILAMENT NETWORKS – NANONET
Program: COST
Project leader: Doc. MVDr. Žilka Norbert DrSc.
Duration: 25.5.2010 – 24.5.2014
Patologické štiepenie tau: samoobnovujúci sa propagátor neurofibrilárnej degenerácie v Alzheimerovej chorobe
Tau truncation: the self-renewing propagator of neurofibrillary degeneration in Alzheimer’s disease
Program: UNIDO
Project leader: Mgr. Kováčech Branislav PhD.
Duration: 1.1.2011 – 31.12.2013
JUMPAHEAD – Koordinačná aktivita na podporu implementácia inociatívy Spoločné programovanie v boji proti neurodegenračným ochoreniam, zvlášť Alzheimerovej chorobe.
COORDINATION ACTION IN SUPPORT OF THE IMPLEMENTATION OF A JOINT PROGRAMMING INITIATIVE FOR COMBATING NEURODEGENERATIVE DISEASES, IN PARTICULAR ALZHEIMER‘S DISEASE
Program: FP7
Project leader: Dr. h. c. prof. MVDr. Novák Michal DrSc.
Duration: 1.9.2010 – 31.8.2013
ALCOVE – Spoločná európska evaluácia problematiky Alzheimerovej choroby
ALzheimer COoperative Valuation in Europe
Program: Multilateral – other
Project leader: Dr. h. c. prof. MVDr. Novák Michal DrSc.
Duration: 1.4.2011 – 31.3.2013
Fosforylovaný tau proteínu ako biomarker porúch chovania v priebehu neurodegenerácie
The role of phosphorylated tau protein in behavioral decline during neurodegeneration
Program: Bilateral – other
Project leader: Dr. h. c. prof. MVDr. Novák Michal DrSc.
Duration: 1.1.2010 – 31.12.2011
Nesprávne zvinutý tau proteín a antioxidačné obranné systémy v tauopátiách
Misfolded tau protein and oxidative defense system in tauopathies
Program: UNIDO
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.1.2009 – 31.12.2011

National

ASTRO-AD – 3D in vitro model Alzheimerovej choroby s využitím astrocytov derivovaných z ľudských indukovaných pluripotentných kmeňových buniek
3D In vitro Modelling of Alzheimer’s Disease using Astrocytes derived from Induced Pluripotent Stem Cells
Program: SRDA
Project leader: prof. MUDr. Syková Eva DrSc.
Duration: 1.8.2018 – 30.6.2021
TraumiRNA – Identifikácia molekulových mechanizmov indukovaných traumatickým poškodením mozgu u hráčov ľadového hokeja
Identification of molecular mechanisms induced by traumatic brain injury in ice hockey players
Program: SRDA
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.8.2018 – 30.6.2021
Neuronálne koreláty kognitívnej dysfunkcie Alzheimerovej choroby
Neuronal correlates of cognitive dysfunction in Alzheimer`s disease
Program: VEGA
Project leader: MVDr. Uhrínová Ivana PhD.
Duration: 1.1.2018 – 31.12.2020
Tryptofán kynurenínová signálna dráha v tauopátiách a jej neuroprotektívna úloha s využitím v terapii
The tryptophan kynurenine pathway- therapeutic strategy for neuroprotection in tauopathies
Program: VEGA
Project leader: Mgr. Majerová Petra PhD.
Duration: 1.1.2018 – 31.12.2020
Vplyv patologického Tau proteínu na neuronálnu diferenciáciu a mitochondriálny metabolizmus
Effect of pathological Tau protein on neuronal differentiation and mitochondrial metabolism
Program: VEGA
Project leader: Mgr. Weisová Petronela PhD.
Duration: 1.1.2018 – 31.12.2020
Využitie zvieracích modelov pre tauopátie na identifikáciu molekulárnych dráh podieľajúcich sa na etiológii neurofibrilárnej degenerácie
Use of animal models for tauopathies for identification of molecular pathways involved in the etiology of neurofibrillary degeneration
Program: VEGA
Project leader: Ing. Hanes Jozef PhD.
Duration: 1.1.2018 – 31.12.2020
TAUPET – Vývoj nových neurozobrazovacích prístupov na predklinickú diagnostiku tauopatií využívajúcich transportné peptidy pre tau-špecifické nanoprotilátky
Development of new neuro-imaging approaches for preclinical diagnosis of tauopathies using transport peptides for tau specific nanobodies
Program: Other projects
Project leader: PharmDr. Kováč Andrej PhD.
Duration: 1.12.2018 – 31.12.2020
Zmeny v hladine cirkulujúcich miRNA u hráčov ľadového hokeja po úrazoch hlavy: potenciálny marker poškodenia mozgu
Changes in plasmatic miRNA level in ice-hockey players after the head injury: potential marker of traumatic brain injury
Program: VEGA
Project leader: prof. RNDr. Kontseková Eva DrSc.
Duration: 1.1.2018 – 31.12.2020
Štúdium funkčných bio-implantátov a bunkovej terapia pre regeneráciu CNS
Study of functional bio-implants and cell therapy for the CNS regeneration
Program: SRDA
Project leader: doc. MVDr. Čížková Daša DrSc.
Duration: 1.7.2016 – 30.6.2020
Využitie animálnych modelov pre tauopátie na identifikáciu molekulárnych dráh podieľajúcich sa na etiológii neurofibrilárnej degenerácie
Use of animal models for tauopathies for identification of molecular pathways involved in the etiology of neurofibrillary degeneration
Program: SRDA
Project leader: Mgr. Kováčech Branislav PhD.
Duration: 1.7.2017 – 30.6.2020
Imunogenetické markery u slovenských pacientov s Alzheimerovou chorobou
Immunogenetic markers in Slovak patients with Alzheimer´s disease
Program: VEGA
Project leader: MUDr., Mgr. Hromádka Tomáš PhD.
Duration: 1.1.2016 – 31.12.2019
Modelovanie interakčných mechanizmov medzi neurónmi a gliovými bunkami v Alzheimerovej chorobe
Modeling of interactions between neurons and glial cells in Alzheimer\’s disease
Program: VEGA
Project leader: RNDr. Žilková Monika PhD.
Duration: 1.1.2017 – 31.12.2019
Vplyv stravy bohatej na tuky na fyziólogiu neurónov CNS, funkciu synapsií a pathologické procesy v neurodegenerácii
The effect of high-fat diet on the physiology of CNS neurons, their synapses and pathological processes in neurodegeneration
Program: VEGA
Project leader: MSc. Jadhav Santosh PhD.
Duration: 1.1.2017 – 31.12.2019
MEITEC_PRE_CNS – Vývoj MEtódy na stratifikáciu pacientov po traumatickom poškodení mozgu a Identifikáciu nových TErapeutických Cieľov PRE personalizovanú liečbu a prevenciu neurodegenerácie
Program: Other projects
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.12.2018 – 31.12.2019
Dokáže aktívna stimulácia mozgu zastaviť šírenie neurofibrilárnej degenerácie?
Is it possible to stop the spreading of neurofibrillary degeneration by active stimulation of the brain?
Program: VEGA
Project leader: Doc. MVDr. Žilka Norbert DrSc.
Duration: 1.1.2016 – 31.12.2018
Inhibícia expresie prirodzene nezvinutých proteínov a jej dôsledky pre progresiu neurodegeneratívnych zmien
Inhibtion of expression of natively unfolded proteins and its consequence for progression of neurodegeneration
Program: VEGA
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.1.2016 – 31.12.2018
MOLEKULÁRNY PROFIL MIRNA A ZMENY GÉNOVEJ EXPRESIE V MODELI ĽUDSKÝCH TAUOPATIÍ
Molecular profiling of miRNA and gene expression changes in a model of human tauopathy
Program: VEGA
Project leader: RNDr. Čente Martin PhD.
Duration: 1.1.2015 – 31.12.2018
Starnutie imunitného systému a biologické markery imunosenescencie
The aging of the immune system and biomarkers of human immunosenescence
Program: VEGA
Project leader: RNDr. Prčina Michal PhD.
Duration: 1.1.2016 – 31.12.2018
ŠTRUKTÚRA SEKVENČNE HOMOLÓGNYCH EPITOPOV VIACNÁSOBNE PRÍTOMNÝCH NA MOLEKULE PRIRODZENE NEUSPORIADANÉHO PROTEÍNU TAU
Structural study of multiple homologous epitopes present on the molecule of intrinsically disordered protein tau
Program: VEGA
Project leader: Ing. Cehlár Ondrej PhD.
Duration: 1.1.2015 – 31.12.2018
Zmeny funkcie kôrových neurónov pri Alzheimerovej chorobe
Functional impact of Alzheimer\’s disease on cortical neurons
Program: VEGA
Project leader: MUDr., Mgr. Hromádka Tomáš PhD.
Duration: 1.1.2016 – 31.12.2018
MODEL BUNKOVEJ KOMUNIKÁCIE MEDZI NERVOVÝM A IMUNITNÝM SYSTÉMOM V ALZHEIMEROVEJ CHOROBE
The model of the neuroimmune crosstalk in Alzheimer´s disease
Program: SRDA
Project leader: Doc. MVDr. Žilka Norbert DrSc.
Duration: 1.7.2015 – 30.6.2018
VÝVOJ NOVÉHO PEPTIDOVÉHO SYSTÉMU PRE TRANSPORT LIEČIV DO MOZGU
Development of novel peptide based system for delivery of therapeutics into the brain
Program: SRDA
Project leader: PharmDr. Kováč Andrej PhD.
Duration: 1.7.2015 – 30.6.2018
Nová kombinovaná terapia na báze alginátových biomateriálov a trofických faktorov pre obnovu poranenej miechy
A novel combined therapy based on alginate biomaterials and trophic factors for spinal cord injury repair
Program: SRDA
Project leader: doc. MVDr. Čížková Daša DrSc.
Duration: 1.1.2016 – 31.12.2017
POŠKODENIE MOZGOVO-CIEVNEJ BARIÉRY V PROSTREDÍ NEURODEGENERÁCIE U TRANSGÉNNYCH POTKANÍCH MODELOV PRE TAUOPÁTIE
Damage of the blood-brain barrier of transgenic rat models for tauopathies
Program: VEGA
Project leader: PharmDr. Kováč Andrej PhD.
Duration: 1.1.2015 – 31.12.2017
BIOFYZIKÁLNA ANALÝZA N-KONCOVEJ DOMÉNY PROTEÍNU TAU MODEL PRE PRIRODZENE NEUSPORIADANÝ POLYPEPTID: DÔSLEDKY PRE NEURODEGENERAČNÉ TAUOPÁTIE
Biophysics and structure of intrinsically disordered polypeptides studied on the N-terminal tail of tau protein: implications for neurodegenerative tauopathies
Program: VEGA
Project leader: RNDr. Škrabana Rostislav PhD.
Duration: 1.1.2013 – 31.12.2016
KONVERZIA NEURONÁLNÉHO PROTEÍNU TAU NA PATOLOGICKÉ FORMY VO ZVIERACOM MODELI NEUROFIBRILÁRNEJ DEGENERÁCIE
Conversion of the neuronal protein tau into pathological forms in the animal model of neurofibrillary degeneration
Program: VEGA
Project leader: Mgr. Kováčech Branislav PhD.
Duration: 1.1.2013 – 31.12.2016
MOLEKULÁRNE MECHANIZMY DYSREGULÁCIE PROTEOSTÁZY V NEURODEGENERATÍVNYCH PROTEINOPÁTIÁCH
Identification of molecular mechanisms underlying dysregulated proteostasis in neurodegenerative proteinopathy
Program: VEGA
Project leader: RNDr. Žilková Monika PhD.
Duration: 1.1.2014 – 31.12.2016
ETIOPATOGENÉZA NEURODEGENERATÍVNYCH OCHORENÍ: VÝZNAM POSTTRANSKRIPČNEJ ÚPRAVY RNA PRE VZNIK A PROGRESIE SPORADICKÝCH TAUOPÁTIÍ A ALZHEIMEROVEJ CHOROBY
Etiopathogenesis of neurodegenerative diseases: focus on RNA processing regulation in development and progression of sporadic tauopathies and Alzheimer´s disease
Program: SRDA
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.10.2013 – 30.9.2016
ŠTÚDIUM FUNKCIE TAU PROTEÍNU V JADRÁCH NEURÓNOV
Studies of tau protein functions in nuclei of neurons
Program: VEGA
Project leader: Mgr. Baráth Peter PhD.
Annotation: Neurofibrillary tangles, one of the hallmarks of Alzheimer\’s disease (AD),are composed of missfolded tau protein that belongs to the family of microtubule-associated proteins. The transition between normal and pathological tau proteins is driven by post-translational modifications and partial proteolytic cleavage. It is generally assumed that the main function of tau involves regulation of the dynamics of neuronal microtubules. Recently, this typical cytosolic protein has been shown to translocate to the nucleus where it might participate in DNA protection upon stress. Within the project, we will study nuclear tau shuttling mechanism using cellular models expressing truncated forms, some of which cause development of AD-like symptoms in transgenic rat. We will also explore the mechanism of DNA protection that includes description of nuclear tau interactome and FISH analysis of chromosomal regions recognized by tau. The study will provide new perspective on physiological and pathological roles of tau protein.
Duration: 1.1.2012 – 31.12.2015
UBIQUITÍN- PROTEAZÓMOVÝ SYSTÉM A JEHO AKTIVITA V BUNKOVOM MODELY NEURODEGRADÁCIE: IMPLIKÁCIE PRE ETIOPATOGENÉZU DEGENERATÍVNYCH OCHORENÍ MOZGU
Ubiquitin proteasomal system and it’s activity in cellular model of neurodegeneration: implications for etiopathogenesis of degenerative diseases of brain
Program: VEGA
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.1.2013 – 31.12.2015
Brain centrum – CENTRUM EXCELENTNOSTI PRE VÝSKUM MOZGU SAV
Program: Centrá excelentnosti SAV
Project leader: Doc. MVDr. Žilka Norbert DrSc.
Duration: 4.8.2011 – 3.8.2015
MECHANIZMUS INTERAKCIE IMUNITNÉHO A NERVOVÉHO SYSTÉMU V PROCESE NEURODEGENERÁCIE MOZGU
Mechnism of immune and neuronal system interaction in the brain during neurodegeneration
Program: SRDA
Project leader: RNDr. Žilková Monika PhD.
Duration: 1.7.2012 – 30.6.2015
RIZIKOVÉ FAKTORY A PROTEOMICKÝ RUKOPIS KOGNITÍVNYCH DYSFUNKCIÍ ANIMÁLNYCH MODELOV PRE ĽUDSKÉ DEMENCIE
Risk factors and proteomic signature of cognitive dysfunctions in animal models for human dementias
Program: SRDA
Project leader: Doc. MVDr. Žilka Norbert DrSc.
Duration: 1.7.2012 – 30.6.2015
ANALÝZY INERAKČNÝCH PARTNEROV PRIÓNOVÉHO PROTEÍNU A ICH FUNKČNÝ VÝZNAM
Analysis of prion protein interaction partners and their functional significance
Program: VEGA
Project leader: prof. RNDr. Kontseková Eva DrSc.
Duration: 1.1.2012 – 31.12.2014
VPLYV RNA SEKUNDÁRNEJ ŠTRUKTÚRY NA EFEKTIVITU ZOSTRIHU PREKURZOROVEJ MRNA. IMPLIKÁCIA PRE REGULÁCIU SYNTÉZY TAU EXÓN 10 +/- IZOFORIEM
Effect RNA secondary structure on RNA splicing effciency. Implication for regulation sythesis of tau exon10 +/-
Program: VEGA
Project leader: Mgr. Královičová Jana PhD
Duration: 1.1.2012 – 31.12.2014
JE STRES JEDNÝM Z PODSTATNÝCH FAKTOROV NEURODEGENERAČNÉHO PROCESU PRI ALZHEIMEROVEJ CHOROBE?
Is stress a crucial factor in the process of neurodegeneration accompanying Alzheimer´s disease?
Program: SRDA
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.5.2011 – 31.10.2014
TauDecode – IDENTIFIKÁCIA POST-TRANSLAČNÝCH MODIFIKÁCIÍ NEURONÁLNEHO PROTEÍNU TAU ZODPOVEDNÝCH ZA NEUROFIBRILÁRNU DEGENERÁCIU V TAUOPÁTIÁCH.
Identification of the posttranslational modifications of the neuronal protein tau leading to neurofibrillary degeneration in tauopathies
Program: SRDA
Project leader: Mgr. Kováčech Branislav PhD.
Annotation: Neurofibrillary degeneration consisting of misfolded neuronal protein tau is the key pathological feature of tauopathies, affecting about 13% of people over the age of 65 and half of those over 85 in the developed countries. The extent of the tau pathology directly correlates with the clinical progression of the disease. It is assumed that halting the tau misfolding process in neurofibrillary pathology would lead to successful therapies preventing the cognitive decline. Hyperphosphorylation and truncation of tau are thought to play the principal role in the induction of its pathology. However, the identity and temporal order of the individual phosphorylation events (there are 45 confirmed phospho-sites on tau) that are required for its misfolding have not been revealed, yet. Furthermore, the temporal relationship of truncation and phosphorylation events on tau is also unknown. In this project we will address the question of the identity and temporal order of the individual phosphorylation patterns and truncation events in the misfolding process of normal tau protein into insoluble aggregates. We will use a unique rat model faithfully reproducing all aspects of the complete cascade of human neurofibrillary degeneration. The results will thus provide a clue for the understanding the paradox how can a highly soluble structureless flexible protein turn insoluble and highly structured in the disease.
Duration: 1.5.2011 – 30.4.2014
ANALÝZA BIOMARKEROV V CEREBROSPINÁLNEJ TEKUTINE TRANSGÉNNYCH ANIMÁLNYCH MODELOV PRE ĽUDSKÉ TAUOPATIE.
Analysis of biomarkers in cerebrospinal fluid in transgenic animal models for human tauopathies.
Program: VEGA
Project leader: MUDr. Kosoň Peter PhD.
Duration: 1.1.2011 – 31.12.2013
METABOLOMICKÁ ANALÝZA POTKANIEHO MODELU PRE TAUOPÁTIE.
Metabolomic analysis of rat model of tauopathy.
Program: VEGA
Project leader: Dr. h. c. prof. MVDr. Novák Michal DrSc.
Duration: 1.1.2011 – 31.12.2013
MITOCHONDRIÁLNE OXIDAČNO-REDUKČNÉ SIGNÁLNE DRÁHY V PATOGENÉZE DEGENERÁCIE CENTRÁLNEHO NERVOVÉHO SYSTÉMU.
Mitochondrial redox signaling pathways in the pathogenesis of degeneration of central nervous system.
Program: VEGA
Project leader: RNDr. Čente Martin PhD.
Duration: 1.1.2011 – 31.12.2013
MOLEKULOVÝ MECHANIZMUS BUNKOVEJ SMRTI PRI ALZHEIMEROVEJ CHOROBE.
Molecular mechanism of cell death in Alzheimer’s disease.
Program: VEGA
Project leader: RNDr. Žilková Monika PhD.
Duration: 1.1.2011 – 31.12.2013
PROTEOMICKÁ ANALÝZA ZDRAVÉHO A CHORÉHO TAU PROTEÍNU U ALZHEIMEROVEJ CHOROBY.
Proteomic analysis of physiological and pathological tau protein by Alzheimer´s disease.
Program: VEGA
Project leader: MUDr. Novák Petr PhD.
Duration: 1.1.2011 – 31.12.2013
ŠTÚDIUM RÔZNYCH ÚNIKOVÝCH STRATÉGIÍ NEUROINVAZÍVNYCH KMEŇOV FRANCISELLA A BORRELIA PRED KOMPLEMENTOVÝM SYSTÉMOM.
Study of multiple complement evasion strategies used by neuroinvasive Francisella and Borrelia.
Program: VEGA
Project leader: Prof. MVDr. Mikula Ivan DrSc.
Duration: 1.1.2011 – 31.12.2013
ZÁPALOVÉ DRÁHY OVPLYVNENÉ GENETICKÝM POZADÍM V TAUOPATII.
Inflammatory pathways influenced by the gentic background in tauopathy.
Program: VEGA
Project leader: Doc. MVDr. Žilka Norbert DrSc.
Duration: 1.1.2011 – 31.12.2013
KOMPLEXNÝ VÝSKUM ŠTRUKTÚRY PRIRODZENE NEUSPORIADANÉHO PROTEÍNU TAU VYSTUPUJÚCEHO V NEURODEGENERAČNÝCH OCHORENIACH.
Complex approach to structural study of intrinsically disordered protein tau associated with neurodegenerations.
Program: SRDA
Project leader: RNDr. Škrabana Rostislav PhD.
Duration: 1.9.2009 – 31.8.2013
SKRÍNINGOVÝ SYSTÉM PRE IDENTIFIKÁCIU POTENCIÁLNYCH BIOLOGICKÝCH MARKEROV PRE SKORÚ DIAGNOSTIKU PARKINSONOVEJ CHOROBY
Program: EU Structural Funds Research & Development
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.11.2010 – 30.4.2013
MOLEKULOVÉ MECHANIZMY NEUROTOXICITY INDUKOVANÉ EXPRESIOU PRIRODZENE NEZVINUTÝCH PROTEÍNOV.
Molecular mechanisms of neurotoxicity induced by expression of naturaly unfolded proteins
Program: VEGA
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.1.2010 – 31.12.2012
MONOKLONOVÉ PROTILÁTKY AKO NÁSTROJ NA ANALÝZU KONFORMAČNÝCH ZMIEN TAU PROTEÍNU PRI ALZHEIMEROVEJ CHOROBE
Monoclonal antibodies as a tool for study of conformational changes of tau protein in Alzheimer´s disease
Program: VEGA
Project leader: RNDr. Paulenka-Ivanovová Natália PhD.
Duration: 1.1.2010 – 31.12.2012
PRIRODZENE NEZVINUTÝ PROTEÍN TAU A JEHO ŠTRUKTURÁLNE ZMENY ANALYZOVANÉ POMOCOU IMUNOLOGICKÉHO IMPRINTU – KONFORMAČNE-ZÁVISLEJ MONOKLONOVEJ PROTILÁTKY
Intrinsically disordered protein tau and its structural changes analyzed by its immunological imprint – conformation-specific monoclonal antibody
Program: VEGA
Project leader: Mgr. Kováčech Branislav PhD.
Duration: 1.1.2010 – 31.12.2012
ŠTÚDIUM ŠTVRTEJ MIKROTUBULY-VIAŽÚCEJ OBLASTI NEUSPORIADANÉHO PROTEÍNU TAU KOMPLEMENTÁRNYMI METÓDAMI ŠTRUKTÚRNEJ BIOLÓGIE VO VZŤAHU K FYZIOLÓGII A PATOLÓGII TAU
Fourth microtubule-binding region of disordered tau protein studied by complementary methods of structural biology: insight into its role in physiology and pathology
Program: VEGA
Project leader: RNDr. Škrabana Rostislav PhD.
Duration: 1.1.2010 – 31.12.2012
VPLYV PATOLOGICKÝCH FORIEM TAU PROTEÍNU NA ŠTRUKTURÁLNE ZMENY NEUROVASKULÁRNEJ JEDNOTKY U POTKANIEHO MODELU PRE ALZHEIMEROVU CHOROBU
Impact of pathological forms of tau protein on structural changes of neurovascular unit in the rat model of Alzheimer’s disease
Program: VEGA
Project leader: Ing. Bugoš Ondrej PhD
Duration: 1.1.2010 – 31.12.2012
TRANSKRIPČNÁ A PROTEOMICKÁ ANALÝZA OXIDAČNO-REDUKČNÉHO SYSTÉMU V NEURÓNOCH EXPRIMUJÚCICH PATOLOGICKÉ FORMY PROTEÍNU TAU
Transcriptional and proteomic analysis of redox system in neurons expressing pathological tau protein isoforms
Program: SRDA
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.9.2009 – 31.8.2012
PRIONÓZY PRENOSNÉ NA ČLOVEKA: VÝSKUM A VÝVOJ BUNKOVÉHO MODELU S POTENCIÁLNYM VYUŽITÍM V APLIKAČNEJ SFÉRE.
Program: EU Structural Funds Research & Development
Project leader: prof. RNDr. Kontseková Eva DrSc.
Duration: 1.10.2009 – 30.11.2011
IMUNITA V TAUOPATIÁCH – DOPAD AKTIVÁCIE A SUPRESIE IMUNITNÉHO SYSTÉMU NA NEURODEGENERÁCIU V TRANSGÉNNOM MODELI POTKANA EXPRIMUJÚCOM SKRÁTENÚ FORMU TAU PROTEÍNU
Program: SRDA
Project leader: Ing. Hanes Jozef PhD.
Duration: 1.9.2009 – 31.8.2011
potkan ako model – Molekulová analýza postranslačných modifikácii tau proteínu v priebehu ontogenézy potkana a ich význam pre modelovanie tau kaskády pri tauopatiách.
Molecular analysis of postranslational modifications of tau protein during ontogenesis of rat and their implication for modelling of tau cascade in tauopathies.
Program: SRDA
Project leader: prof. RNDr. Kontseková Eva DrSc.
Duration: 1.6.2008 – 31.12.2010
Nesprávne zvinutý tau proteín a antioxidačné obranné systémy v tauopátiách
Misfolded tau protein and oxidative defense system in tauopathies
Program: Podpora MVTS z prostriedkov SAV
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.1.2010 – 31.12.2010
Rekonštrukcia neurofibrilárnej degenerácie Alzheimerovho typu v jednej bunke.
In vitro reconstruction of Alzheimer’s disease type neurofibrillary degeneration
Program: VEGA
Project leader: RNDr. Čente Martin PhD.
Duration: 1.1.2008 – 31.12.2010
Tvorba, akumulácia a degradácia aberantných proteínov v patogenéze chronických neurodegeneračných ochorení centrálneho nervového systému
Generation, accumulation and degradation of aberrant proteins in the pathogenesis of chronic neurodegenerative diseases of central nervous system
Program: SRDA
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.6.2008 – 31.12.2010
Využitie kmeňových buniek pre imunomodulačnú a regeneračnú liečbu neurodegeneračných a zápalových procesov spojených s Alzheimerovou chorobou
Regenerative and immunomodulatory cell therapy of Alzheimer’s disease neurodegeneration using bone marrow stem cell clones
Program: SRDA
Project leader: Doc. MVDr. Žilka Norbert DrSc.
Duration: 1.6.2008 – 31.12.2010
Tauopátie: Molekulová analýza hyperfosforylovaných foriem tau proteínu a ich vplyv na poškodenie kognitívnych a senzorimotorickych funkcií transgénnych potkanov
Tauopathies: Molecular analysis of the hyperphosphorylated forms of the tau protein and their impact on the deterioration of the cognitive and sensorimotor functions of the transgenic rats.
Program: VEGA
Project leader: RNDr. Stožická Zuzana PhD.
Duration: 1.1.2008 – 1.1.2010
DNA analýza familiárnych foriem tauopátií na Slovensku
DNA analysis of familial forms of tauopathies in Slovakia
Program: SRDA
Project leader: Dr. h. c. prof. MVDr. Novák Michal DrSc.
Duration: 1.2.2007 – 31.12.2009
Fyziologické štr – Štruktúra fyziologických konformácií prirodzene neusporiadaneho proteínu tau: dôsledky pre neurodegeneráciu Alzheimerovho typu
Structure of physiological conformations of intrinsically disordered tau protein: implications for Alzheimer\’s type of neurodegeneration
Program: SRDA
Project leader: RNDr. Škrabana Rostislav PhD.
Duration: 1.2.2007 – 31.12.2009
Biochemické aspekty konverzie priónového proteínu PrP c na patologickú formu PrP Sc
Biochemical aspects of normal form prion protein PrP c conversion into the pathological PrP Sc
Program: VEGA
Project leader: RNDr. Imrichová Denisa PhD
Duration: 1.1.2007 – 1.12.2009
Inhibítory tau fosforylácie ako modulátory patogenézy pri Alzheimerovej chorobe
Inhibitors of tau phosphorylation as modulators of Alzheimer s disease pathogenesis
Program: VEGA
Project leader: Ing. Hanes Jozef PhD.
Duration: 1.1.2007 – 1.12.2009
Nitrácia tau proteínov ako potenciálne významný rizikový faktor v patogenéze Alzheimerovej choroby
Nitration of tau proteins as potentially important risk factor in the pathogenesis of Alzheimer s disease
Program: VEGA
Project leader: doc. RNDr. Filipčík Peter CSc.
Duration: 1.1.2007 – 1.12.2009